ASMBClinical Trials•globenewswire•
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
Sentiment:Positive (85)
Summary
– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo over 29-day evaluation period –
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 8, 2025 by globenewswire